Effect of continuous positive airway pressure (CPAP) therapy on arterial stiffness in patients with obstructive sleep apnoea/hypopnoea syndrome (OSAHS)

Aortic distensibility in obstructive sleep apnoea/hypopnoea syndrome (OSAHS) using cardiovascular magnetic resonance imaging and and pulse wave analysis: effect of continuous positive airway pressure (CPAP) therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48783995

Enrollment

Registered

2010-07-27

Start date

2007-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) Nervous System Diseases Sleep disorders

Interventions

Patients meeting the inclusion criteria will be recruited from the Department of Sleep Medicine. This is a randomised controlled crossover trial with 12 weeks in each limb. The active treatment limb c

total duration of treatment is therefore approximately 24 weeks in total for intervention group. Control subjects were assessed once and there was no further follow up after this.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Both: 1. Males and females aged 18 - 65 years Patients: 2. Apnoea Hypopnoea Index (AHI) greater than or equal to 15 at polysomnography 3. CPAP naive 4. Ability to give written informed consent Control subjects: 5. AHI less than or equal to 10 at polysomnography 6. Epworth Sleepiness Score (ESS) less than 11 7. Ability to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Inability to give written informed consent 2. Known cardiovascular disease or diabetes 3. History of respiratory failure 4. Medications affecting blood pressure 5. Reported sleepiness when driving or those who drive for a living 6. Claustrophobia precluding magnetic resonance imaging (MRI) scanning 7. Implanted/foreign bodies precluding MRI scanning

Design outcomes

Primary

Measure	Time frame
Arterial stiffness as measured by PWV/PWA and aortic distensibility as measured by cardiovascular MRI, at timepoints 0, 12 and 24 weeks	—

Secondary

Measure	Time frame
Measured at timepoints 0, 12 and 24 weeks: 1. Endothelial function as measured by pulse wave analysis (before and after administration of GTN and salbutamol) 2. Blood pressure changes	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026